Life science VC MPM Capital is looking to boost funding for a select series of early-stage biotechs with a new $400 million fund.
J&J has joined AbbVie as a partner for Morphic and its small-molecule integrin platform, pledging up to $725 million to the cause.
What if we could prevent opioid addiction before it starts? Reducing exposure to opioids after surgery through better non-opioid pain management options can…
In our EuroBiotech roundup this week, Gamida inks pact with Editas, Autolus posts CAR-T data and Calypso raises €20 million.
In this week's EuroBiotech Report, Disley lands at Mogrify, Moroney set to leave MorphoSys and Arix reappoints Anderson as CEO.
Cerevel Therapeutics is bringing on Otsuka’s Raymond Sanchez, to serve as chief medical officer and take its CNS assets into phase 3.
Bristol-Myers is testing its leukemia therapy Sprycel in a phase 2 combo study with the anti-PD-1 drug Opdivo in non-small cell lung cancer patients.
The FDA placed a partial clinical hold on a bispecific antibody in development for acute myeloid leukemia following reports of two patient deaths.
Pluristem has reached a stellar deal with NASA that will see its cell therapies tested against the health problems caused by spending time in space.
The cost-cutting actions come as Vical tries to eke out its cash while looking into strategic alternatives.
Moroney will step down as CEO after his current contract expires in June 2020, or earlier if a successor is appointed before that time.